Another Activist Investor Joins Calls For GSK Leadership Review
Bluebell Capital Has Already Ousted One CEO
A second activist investor has called for GSK to consider replacing Emma Walmsley as CEO
, and has underlined competitive threats to a key pipeline candidate.
You may also be interested in...
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.
Bintrafusp alfa was once seen as a blockbuster contender by the partners but GSK’s withdrawal narrows further its chances of success.
Once the consumer health division is spun out in mid-2022, a leaner ‘new GSK’ must set about delivering on its promising pipeline – and proving its skeptics wrong.